CERo Therapeutics (CERO) vs. Its Peers Critical Review

CERo Therapeutics (NASDAQ:CERO) is one of 248 public companies in the “MED – DRUGS” industry, but how does it weigh in compared to its competitors? We will compare CERo Therapeutics to similar businesses based on the strength of its risk, dividends, profitability, analyst recommendations, earnings, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and target prices for CERo Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1	3	0	0	1.75
CERo Therapeutics Competitors	2235	3804	9860	411	2.52

CERo Therapeutics presently has a consensus price target of $45.00, suggesting a potential upside of 40,809.09%. As a group, “MED – DRUGS” companies have a potential upside of 55.60%. Given CERo Therapeutics’ higher possible upside, equities research analysts plainly believe CERo Therapeutics is more favorable than its competitors.

Profitability

This table compares CERo Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
CERo Therapeutics Competitors	-20,891.78%	-168.76%	-18.35%

Valuation and Earnings

This table compares CERo Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CERo Therapeutics	N/A	-$8.30 million	0.00
CERo Therapeutics Competitors	$1.08 billion	$57.53 million	2.91

CERo Therapeutics’ competitors have higher revenue and earnings than CERo Therapeutics. CERo Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “MED – DRUGS” companies are held by institutional investors. 0.4% of CERo Therapeutics shares are held by company insiders. Comparatively, 13.5% of shares of all “MED – DRUGS” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

CERo Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, CERo Therapeutics’ competitors have a beta of -0.96, meaning that their average stock price is 196% less volatile than the S&P 500.

Summary

CERo Therapeutics competitors beat CERo Therapeutics on 9 of the 13 factors compared.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.